Harmony Biosciences Q2 revenue rises 16% to $200.5 million; 2025 guidance reaffirmed
Harmony Biosciences reported second-quarter 2025 net product revenue of $200.5 million, up 16% from $172.8 million a year earlier, and GAAP net income of $39.8 million, or $0.68 per diluted share, compared with $11.6 million, or $0.20, in Q2 2024. The company reaffirmed its full-year 2025 net product revenue guidance of $820 million to $860 million, so higher sales and profit were reported with the annual forecast unchanged.
Key points
- Q2 2025 net product revenue was $200.5 million, up from $172.8 million; average patients rose by 400 to 7,600
- GAAP diluted EPS was $0.68 versus $0.20 in Q2 2024; non-GAAP adjusted diluted EPS was $0.92 versus $0.43
- Full-year 2025 net product revenue guidance reaffirmed at $820 million to $860 million
- Cash, cash equivalents and investments were $672.3 million as of June 30, 2025; Fragile X Phase 3 topline data expected in Q3 2025
The filing
Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.